Questions: Renal Tubular Acidosis Type 1: Impaired Distal Acid Secretion and Hyperchloremic Acidosis

Question 1

A patient presents with fatigue and is found to have pH 7.28, bicarbonate 14 mEq/L, chloride 113 mEq/L, sodium 138 mEq/L, and a urine pH of 6.5 despite severe systemic acidosis. The anion gap is 11. What is the most likely diagnosis?

• A. Diabetic ketoacidosis — ketoacid accumulation causes metabolic acidosis
• B. Lactic acidosis — tissue hypoxia generates unmeasured organic acid
• C. Type 1 renal tubular acidosis — the distal nephron cannot acidify urine
• D. Respiratory acidosis with metabolic compensation

Answer: (C)

The key diagnostic clue is the paradox: severe systemic acidosis (pH 7.28, low HCO₃) but alkaline urine (pH 6.5). In any other cause of metabolic acidosis, the kidney would compensate by acidifying urine to pH <5.5. Type 1 RTA is the specific failure of alpha-intercalated cells to secrete H+ in the collecting duct, so urine cannot acidify below ~5.3 even when blood is severely acidotic. The normal anion gap (Na − Cl − HCO₃ = 138 − 113 − 14 = 11) rules out unmeasured acid accumulation (DKA, lactic acidosis) — the acidosis is purely from bicarbonate loss with chloride replacement.

Question 2

Why does Type 1 RTA cause hypokalemia rather than the hyperkalemia seen in Type 4 RTA?

• A. The collecting duct increases sodium reabsorption, which pulls potassium into the tubule
• B. Because H+ and K+ compete for secretion in the collecting duct, impaired H+ secretion increases K+ secretion to maintain electroneutrality
• C. Chronic acidosis shifts potassium into cells via Na/K-ATPase activation
• D. Aldosterone levels are suppressed in Type 1 RTA, reducing potassium reabsorption

Answer: (B)

In the collecting duct, H+ and K+ are both secreted by intercalated and principal cells respectively, competing for the electrical driving force created by luminal electronegativity. When H+ secretion is severely impaired in Type 1 RTA, the collecting duct compensates with increased K+ secretion — essentially K+ fills the secretory 'slot' that H+ cannot. The result is progressive urinary potassium wasting and hypokalemia. This contrasts with Type 4 RTA (aldosterone deficiency/resistance), where both H+ and K+ secretion fail together, causing hyperkalemia.

Question 3

In Type 1 RTA, the urine pH cannot fall below approximately 5.3 even when blood pH is severely acidotic — the opposite of what normal kidneys do.

• T. True
• F. False

Answer: True

This paradox is the pathognomonic hallmark of Type 1 (distal) RTA. Normally, the alpha-intercalated cells of the collecting duct can achieve a urine pH as low as 4.5 — an ~800-fold H+ concentration gradient against blood. In distal RTA, the H+-ATPase pump is defective or protons back-leak through a damaged epithelium, so the kidney cannot maintain this gradient. Urine pH stays alkaline even as blood accumulates acid. This urine pH test is diagnostically central: if a patient with metabolic acidosis cannot acidify urine below pH 5.3 after an acid load challenge, Type 1 RTA is confirmed.

Question 4

Type 1 RTA produces a high anion gap metabolic acidosis because accumulated H+ displaces bicarbonate.

• T. True
• F. False

Answer: False

Type 1 RTA produces a normal anion gap (hyperchloremic) metabolic acidosis — not a high anion gap acidosis. High anion gap acidosis occurs when an unmeasured anion accumulates (lactate, ketoacids, toxins). In Type 1 RTA, no such anion is generated. Instead, the kidney fails to regenerate bicarbonate, which is consumed buffering metabolic acid. Chloride replaces the lost bicarbonate to maintain electroneutrality, so the anion gap (Na − Cl − HCO₃) stays normal because both Cl and HCO₃ move in opposite directions. This distinction is clinically important for diagnosis and points toward the correct treatment.

Question 5

Explain why nephrolithiasis develops in Type 1 RTA and why the stones are calcium phosphate rather than calcium oxalate.

Model answer: Two converging mechanisms promote stone formation. First, chronic systemic acidosis mobilizes calcium from bone as a buffer, releasing it into blood and then urine — causing hypercalciuria. Second, because the kidney cannot acidify urine, the urine remains alkaline (pH >5.3). Calcium phosphate (as hydroxyapatite or brushite) is far less soluble in alkaline urine than in acidic urine, so it precipitates readily. Calcium oxalate stones, by contrast, form in acidic conditions. The combination of high urinary calcium and persistently alkaline urine creates the ideal environment for calcium phosphate crystallization.

This is a case where mechanistic reasoning directly predicts the clinical finding. Treatment with potassium citrate addresses all three problems simultaneously: it provides alkali to correct acidosis (reducing bone calcium mobilization and hypercalciuria), it provides potassium to correct hypokalemia, and alkalinizing agents are somewhat protective against calcium phosphate stones at very high pH but more importantly the reduced calcium excretion after acidosis correction dominates the benefit.